Patents Assigned to Academisch Ziekenhuis Maastricht
  • Patent number: 11078544
    Abstract: This disclosure is in the field of molecular biology and medical diagnosis and provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, this disclosure provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: August 3, 2021
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Manon Van Engeland, Leander Pieter Jo Van Neste, Karin Van Den Hurk
  • Publication number: 20210215716
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 15, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Peter Kastner, Manuel Dietrich, André Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Ulrich Schotten
  • Publication number: 20210161457
    Abstract: A method of processing of electrocardiogram includes the steps of providing an electrocardiogram comprising signals in at least two channels; selecting at least two frequency ranges of the signal in each of the said at least two channels; calculating an envelope for the signal in each frequency range in each channel; dividing the calculated envelope of the signal in each frequency range in each channel into QRS complex segment envelopes; and computing an average or median envelope as an average or mean of QRS complex segment envelopes for each frequency range in each channel.
    Type: Application
    Filed: November 25, 2020
    Publication date: June 3, 2021
    Applicants: Institue of Scientific instruments of the Czech Academy of Sciences, v. v. i., St. Anne's Univeristy Hospital Bmo, Charles University, Universiteit Maastricht, Academisch Ziekenhuis Maastricht, CARDION s.r.o.
    Inventors: Pavel Jurak, Josef Halamek, Ivo Viscor, Filip Plesinger, Vlastimil Vondra, Radovan Smisek, Pavel Leinveber, Magdalena Matejkova, Jolana Lipoldova, Miroslav Novak, Karol Curila, Jana Vesela, Frits W. Prinzen, Ivo Nekuda, Vit Nekuda
  • Publication number: 20210156875
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 27, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universitaet Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Jennifer Meessen, Ulrich Schotten
  • Patent number: 10993820
    Abstract: The invention relates to stents, in particular to a stent for insertion in a vein of a human or animal body. The invention also relates to a catheter stent insertion device for inserting a stent according to the invention in a vein of a human or animal body. The invention also relates to a method for inserting a stent according to the invention in a vein of a human or animal body using a catheter stent insertion device according to the invention.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: May 4, 2021
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventor: Cornelis Hendrikus Anna Wittens
  • Patent number: 10890584
    Abstract: A device (100) for detecting an analyte (132) includes a polymer material (112) over a substrate (110); a heat transfer element (114) thermally coupled to the substrate; a temperature modification device (118) thermally coupled to the heat transfer element; a controller (121) to produce a thermal (202) wave emanating from the heat transfer element; a flow cell (122) located and configured to pass a liquid (124) over the polymer material; a temperature sensor (134) to detect a temperature (T2) of the liquid passing over the polymer material; and a processor (123) to calculate a concentration of an analyte (132) in the liquid based at least in part on a phase shift between the thermal wave at the heat transfer element and an attenuated thermal wave (204) in the liquid. Related methods of forming such a device and detecting analytes are also disclosed.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: January 12, 2021
    Assignee: Academisch Ziekenhuis Maastricht
    Inventors: Bart Robert Nicolaas Van Grinsven, Thomas Jan Cleij
  • Patent number: 10617739
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: April 14, 2020
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Patent number: 10383732
    Abstract: An implant, such as a cranial implant, for attachment to a defect in a bone structure having an edge is described. The implant comprises a direction of extension and a rim extending substantially perpendicular to the direction of extension of the implant. The rim is configured to be attached to the edge of the bone structure and comprises at least one mounting portion configured to accommodate a fastener such that at least a portion of the fastener is extendible in a direction extending away from the rim at an angle which is at most acute with respect to the direction of extension of the implant. The implant is configured such that upon placing the implant in the defect, the fastener is extendible into the edge of the bone defect in a controllable manner.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: August 20, 2019
    Assignees: ACADEMISCH ZIEKENHUIS MAASTRICHT, UNIVERSITEIT MAASTRICHT
    Inventors: Maikel Michael Adrianus Beerens, Paul Frans Jozef Laeven, Jules Maria Nikolaas Poukens
  • Patent number: 10324087
    Abstract: A device for detecting an analyte includes a thermocouple having an assay polymer over a surface of the thermocouple. The assay polymer is formulated to bind to the analyte, and a heat transfer property of the assay polymer varies responsive to an amount of the analyte bound thereto. A method of forming a sensor includes providing an assay polymer over a thermocouple. A method for detecting an analyte includes passing a liquid containing an analyte adjacent a thermocouple having an assay polymer over a surface thereof, binding an analyte to the assay polymer, detecting a temperature of the thermocouple, and calculating a concentration of the analyte in the liquid based at least in part on the heat transfer property of the assay polymer.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: June 18, 2019
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Bart Robert Nicolaas Van Grinsven, Thomas Jan Cleij
  • Patent number: 10272248
    Abstract: In some examples, controlling delivery of CRT includes delivering ventricular pacing according to a sequence of different values of at least one of A-V delay or V-V delay, and acquiring one or more electrograms from respective vectors. For each of the different values of the at least one of A-V delay or V-V delay, at least one of a QRS amplitude or a QRS area may be determined based on the one or more electrograms, and a target change in QRS amplitude or QRS area between adjacent ones of the values of the at least one of A-V delay or V-V delay of the sequence may be identified. In response to the identification of the target change, the implantable medical device may deliver the ventricular pacing at a value of the at least one of A-V delay or V-V delay determined based on the identification to provide CRT.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 30, 2019
    Assignees: Medtronic, Inc., Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Elien B. Engels, Kevin Vernooy, Alfonso Aranda Hernandez, Frits W. Prinzen, Jeffrey M. Gillberg
  • Patent number: 10260109
    Abstract: This disclosure is in the field of molecular biology and medical diagnosis and provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, this disclosure provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: April 16, 2019
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Manon Van Engeland, Leander Pieter Jo Van Neste, Karin Van Den Hurk
  • Patent number: 10139407
    Abstract: A method for characterizing bacteria includes passing a liquid containing an analyte comprising a first bacteria and a second bacteria over and in contact with a polymer material on a substrate. The polymer material is formulated to bind to the first bacteria, and the first bacteria binds to the polymer material with a higher affinity than the second bacteria. A heat transfer property of the polymer material varies based on an amount of the analyte bound thereto. The method further includes binding a portion of the first bacteria and the second bacteria of the analyte to the polymer material, removing at least a portion of the second bacteria from the polymer material, detecting a temperature of the substrate, and calculating a concentration of the first bacteria in the liquid based at least in part on the temperature of the substrate.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: November 27, 2018
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Bart Robert Nicolaas Van Grinsven, Thomas Jan Cleij
  • Patent number: 9822414
    Abstract: The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. In particular, the invention provides a method for predicting the in vivo genotoxicity of a compound comprising the steps of performing an Ames test on the compound and determining if the result is positive or negative, followed by a step wherein the gene expression of at least 3 genes is determined in a HepG2 cell, compared to a reference value and predicting that the compound is in vivo genotoxic if the expression level of more than 2 of the genes is above a reference value.
    Type: Grant
    Filed: May 19, 2012
    Date of Patent: November 21, 2017
    Assignees: UNIVERSITEIT MAASTRICHT, ACADEMISCH ZIEKENHUIS MAASTRICHT
    Inventors: Joseph Henri Marie Van Delft, Joseph Catharina Stephanus Kleinjans, Christina Magkoufopoulou, Danyel Gerardus Jacobus Jennen
  • Patent number: 9790545
    Abstract: This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: October 17, 2017
    Assignees: UNIVERSITEIT MAASTRICHT, ACADEMISCH ZIEKENHUIS MAASTRICHT
    Inventors: Jeroen Lambertus Antonius Pennings, Petrus Theodorus Theunissen, Aldert Henrick Piersma
  • Publication number: 20170292950
    Abstract: A method for characterizing bacteria includes passing a liquid containing an analyte comprising a first bacteria and a second bacteria over and in contact with a polymer material on a substrate. The polymer material is formulated to bind to the first bacteria, and the first bacteria binds to the polymer material with a higher affinity than the second bacteria. A heat transfer property of the polymer material varies based on an amount of the analyte bound thereto. The method further includes binding a portion of the first bacteria and the second bacteria of the analyte to the polymer material, removing at least a portion of the second bacteria from the polymer material, detecting a temperature of the substrate, and calculating a concentration of the first bacteria in the liquid based at least in part on the temperature of the substrate.
    Type: Application
    Filed: April 11, 2016
    Publication date: October 12, 2017
    Applicants: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Bart Robert Nicolaas Van Grinsven, Thomas Jan Cleij
  • Publication number: 20170176445
    Abstract: The invention is in the field of medicine and molecular therapeutics. The invention provides means and measures for diagnosis and treatment, in particular for diagnosis and treatment of tumors, more in particular for determining the level of hypoxia in a tumor and for reducing the risk of metastasis of a tumor in a subject. The invention comprises a method wherein a level of exosome-associated GABARAPL1 is determined in a bodily fluid of the subject and wherein an elevated level of exosome-associated GABARAPL1 is indicative of an increased level of hypoxia of the tumor. The invention also comprises an antibody directed against GABARAPL1 for use in the treatment or prevention of cancer.
    Type: Application
    Filed: February 11, 2015
    Publication date: June 22, 2017
    Applicants: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Kasper Mathias Antoon ROUSCHOP, Tom Gertrudis Hubertus KEULERS
  • Patent number: 9611480
    Abstract: The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: April 4, 2017
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Leon Johannes De Windt, Hamid El Azzouzi
  • Patent number: 9528155
    Abstract: The invention is in the field of molecular diagnostics. More in particular it provides marker genes for determining the immunotoxicity of compounds. A method according to the invention employs samples obtained from a cell exposed to a potentially immunotoxic compound and determines expression levels of a number of marker genes in order to distinguish between immunotoxic compounds and non-immunotoxic compounds. More in particular, the invention relates to an in vitro method for determining whether a compound is immunotoxic wherein the expression level of at least one marker gene is determined in a sample obtained from a nucleated cell exposed to the compound, wherein the at least one marker gene is selected from the group consisting of ABCA1, CHAC1, CRIM1 and HMGCS1, and wherein it is concluded that the compound is immunotoxic if the expression level of said at least one marker gene is below or above a predetermined reference value.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: December 27, 2016
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Oscar Leonard Volger, Jia Shao, Adrianus Antonius Cornelis Maria Peijnenburg, Hendrik Van Loveren
  • Patent number: 9408829
    Abstract: The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: August 9, 2016
    Assignees: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, MAASTRICHT UNIVERSITY, ACADEMISCH ZIEKENHUIS MAASTRICHT
    Inventors: Esther Lutgens, Christian Weber, Gerry Nicolaes
  • Patent number: 9393303
    Abstract: The invention is in the field of prevention and medical treatment of liver diseases, in particular non-alcoholic steatohepatitis (NASH). The invention provides means and methods for the treatment of hepatic inflammation, fibrosis and more in particular NASH. More in particular, the invention provides a composition capable of raising anti-oxLDL antibodies in vivo for use in the treatment of liver inflammation or fibrosis.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: July 19, 2016
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Ronit Sverdlov, Veerle Bieghs, Patrick Johannes Jacobus van Gorp